ClinicalTrials.Veeva

Menu

The Acute Effect of a Theacrine-based Supplement on Mobilization of Various Stem Cell Populations.

University of Memphis logo

University of Memphis

Status

Completed

Conditions

Stem Cells

Treatments

Dietary Supplement: NAD3

Study type

Interventional

Funder types

Other

Identifiers

Details and patient eligibility

About

The goal of the study is to determine the acute and short-term supplementation effect of a commercially available theacrine-containing supplement (NAD3) on numbers of various circulating stem cell populations in older adults.

Full description

This is a double-blind, placebo-controlled crossover study with 12 participants randomized to receive either NAD3® or a placebo for seven days. Blood samples are collected after an overnight fast, before and after the seven-day supplementation period, as well as one and two hours after the final supplement/placebo dose. Using flow cytometry, circulating stem cells, including lymphocytoid CD34+ stem cells (CD45dimCD34+), stem cells associated with vascular maintenance and repair (CD45dimCD34+CD309+), CD34+ stem cells linked to a progenitor phenotype (CD45dimCD34+CD309neg), circulating endothelial stem cells (CD45negCD31+CD309+), and mesenchymal stem cells (CD45negCD90+) are quantified.

Enrollment

12 patients

Sex

All

Ages

40 to 70 years old

Volunteers

Accepts Healthy Volunteers

Inclusion criteria

  • Male or Female
  • Age 40-70
  • BMI between 21-34.99 kg/m2
  • Vital signs with in normal range (heart rate 60-100 beats/minute, blood pressure (40-44 years - 125/83, 45-49 years- 127/84, 50-54 years -129/85, 55-59 years - 131/86, >60 - 134/87), 36.4-37.4 degrees Celsius
  • Sedentary to lightly active (2 or fewer days per week of exercise)

Exclusion criteria

  • Female participants who are lactating, pregnant or planning to become pregnant during the study
  • History of use of illicit drugs or other substances of abuse within 12 months of the screening visit (to be determined at screening)
  • Tobacco during the 90 days prior to screening
  • Current use of medication/dietary supplements that claim to or have an effect on age-related processes, e.g. "anti-aging" supplements. Participants must undergo a ≥7-day washout period of no supplementation to be eligible.
  • Known allergy, intolerance or hypersensitivity to NAD3
  • Self-reported active infection or illness of any kind
  • Cognitively impaired and/or unable to give informed consent

Trial design

Primary purpose

Basic Science

Allocation

Randomized

Interventional model

Crossover Assignment

Masking

Triple Blind

12 participants in 2 patient groups, including a placebo group

Test product (NAD3)
Active Comparator group
Description:
344 mg microcrystalline cellulose,156 mg of a proprietary blend of Wasabia japonica (freeze-dried rhizome) cultivar, standardized to NLT 12,000 ppm isothiocyanates, 97.0% Theacrine, Copper Nicotinic Acid chelated complex (17-20% Copper by ICP-Mass spectroscopy) per capsule
Treatment:
Dietary Supplement: NAD3
Placebo
Placebo Comparator group
Description:
500 mg of foodgrade mass, and color-matched microcrystalline cellulose per capsule
Treatment:
Dietary Supplement: NAD3

Trial contacts and locations

1

Loading...

Data sourced from clinicaltrials.gov

Clinical trials

Find clinical trialsTrials by location
© Copyright 2025 Veeva Systems